Third Rock rolls $47m dice on cancer immunotherapy and Jounce 'dream team'
This article was originally published in Scrip
Executive Summary
As one of the founders and the sole funder for Jounce Therapeutics' $47 million Series A venture funding round, Third Rock Ventures has placed a big bet on cancer immunotherapies, but the firm is working with a group of clinicians and researchers hand-picked to ensure that at least some of Jounce's wagers pay off.
You may also be interested in...
Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal
A deal with Celgene Corp. worth $261m up front will save Jounce Therapeutics Inc. from having to wade into the treacherous market for initial public offerings in order to advance and accelerate its immuno-oncology research and development programs.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.